Table 2. Risk factors associated with 28-day mortality and 180-day mortality.
| Variables | 28-day mortality | 180-day mortality | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariable RR [95% CI] | p value | Multivariable RR [95% CI] | p value | Univariable RR [95% CI] | p value | Multivariable RR [95% CI] | p value | |
| Demographic and clinical characteristics | ||||||||
| Age, years | 1.02 [1.00–1.04] | 0.03 | 1.03 [1.00–1.05] | 0.04 | 1.03 [1.01–1.05] | <0.01 | 1.04 [1.02–1.06] | <0.01 |
| Gender | 0.88 [0.51–1.51] | 0.64 | 0.94 [0.60–1.47] | 0.80 | ||||
| Diabetes | 1.00 [0.57–1.77] | 0.99 | 0.93 [0.58–1.49] | 0.77 | ||||
| Hypertension | 1.51 [0.89–2.54] | 0.13 | 1.41 [0.92–2.16] | 0.11 | ||||
| Coronary heart disease | 1.35 [0.76–2.41] | 0.31 | 1.51 [0.96–2.40] | 0.07 | ||||
| Chronic lung disease | 0.64 [0.20–2.04] | 0.45 | 0.82 [0.36–1.87] | 0.63 | ||||
| Chronic renal failure | 1.41 [0.67–2.98] | 0.37 | 1.42 [0.77–2.61] | 0.26 | ||||
| Malignant tumor | 1.26 [0.46–3.48] | 0.66 | 1.51 [0.66–3.46] | 0.33 | ||||
| Cerebrovascular disease | 0.91 [0.48–1.71] | 0.76 | 1.10 [0.67–1.79] | 0.71 | ||||
| Laboratory findings | ||||||||
| WBC, ×109/L | 1.06 [1.02–1.10] | <0.01 | 1.04 [0.98–1.11] | 0.16 | 1.07 [1.04–1.10] | <0.01 | 1.06 [1.01–1.12] | 0.03 |
| Neutrophilic granulocyte percentage, % | 1.05 [1.02–1.08] | <0.01 | 1.01 [0.91–1.12] | 0.84 | 1.05 [1.02–1.07] | <0.01 | 0.95 [1.03–1.12] | 0.44 |
| Lymphocyte percentage, % | 0.93 [0.89–0.98] | <0.01 | 0.96 [0.84–1.10] | 0.55 | 0.95 [0.91–0.98] | <0.01 | 1.00 [0.90–1.11] | 0.99 |
| Platelet count, ×109/L | ||||||||
| Thrombocytopenia, ≤125 | 2.79 [1.65–4.74] | <0.01 | 2.98 [1.48–6.02] | <0.01 | 2.08 [1.32–3.29] | <0.01 | 2.45 [1.32–4.57] | <0.01 |
| Non-thrombocytopenia, >125 | 1 (ref) | - | - | - | 1 (ref) | - | - | - |
| Creatinine, ×109/L | 1.00 [1.00–1.00] | 0.41 | 1.00 [1.00–1.00] | 0.22 | ||||
| Blood urea, mmol/L | 1.00 [0.99–1.01] | 0.60 | 1.00 [1.00–1.01] | 0.60 | ||||
| AST, IU/L | 1.00 [1.00–1.00] | 0.40 | 1.00 [1.00–1.00] | 0.88 | ||||
| ALT, IU/L | 1.00 [1.00–1.00] | 0.84 | 1.00 [1.00–1.00] | 0.65 | ||||
| Total bilirubin, μmol/L | 1.03 [1.00–1.05] | 0.05 | 0.99 [0.96–1.03] | 0.70 | 1.03 [1.01–1.05] | 0.01 | 0.99 [0.97–1.02] | 0.68 |
| Procalcitonin, ng/mL | 1.00 [0.98–1.01] | 0.64 | 0.99 [0.98–1.01] | 0.48 | ||||
| PT, seconds | 1.11 [1.04–1.18] | <0.01 | 0.98 [0.87–1.10] | 0.73 | 1.13 [1.06–1.19] | <0.01 | 1.00 [0.90–1.10] | 0.93 |
| APTT, seconds | 1.02 [1.00–1.04] | 0.02 | 1.02 [1.00–1.04] | 0.05 | 1.03 [1.01–1.04] | <0.01 | 1.00 [1.02–1.04] | 0.01 |
| hs-CTn I, ng/mL | 1.05 [0.80–1.37] | 0.75 | 1.04 [0.83–1.29] | 0.76 | ||||
| D-dimer, μg/L | 1.02 [1.01–1.03] | <0.01 | 0.99 [0.97–1.01] | 0.50 | 1.02 [1.01–1.03] | <0.01 | 0.98 [1.00–1.01] | 0.57 |
| LDH, U/L | 1.00 [1.00–1.00] | 0.04 | 1.00 [1.00–1.00] | 0.35 | 1.00 [1.00–1.00] | 0.01 | 1.00 [1.00–1.00] | 0.15 |
(RR) relative risk; (CI) confidence Interval; (WBC) White blood cell; (AST) Aspartate aminotransferase; (ALT) Alanine aminotransferase; (PT) Prothrombin time; (APTT) Activated partial thromboplastin time; (Hs-CTn I) hypersensitive troponin I; (LDH) Lactate dehydrogenase.